Drug intelligence / Profile preview

PEG@mPt-HF

Development stage: Preclinical
Lead developer: Nanjing Medical University
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

**PEG@mPt-HF** is a preclinical theranostic nanomedicine comprising halofuginone loaded into polyethylene glycol-coated mesoporous platinum nanoparticles. The platinum nanoparticle carrier provides computed tomography contrast and photothermal tumor ablation, while released halofuginone suppresses transforming growth factor beta-associated extracellular-matrix remodeling and collagen deposition. It was developed in mouse breast-cancer models to improve intratumoral delivery, reduce stromal barriers, enhance photothermal antitumor activity, and mitigate the liver toxicity observed with free halofuginone.

Other names: PEG@mPt-HF

Targets

TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on PEG@mPt-HF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEG@mPt-HF.

Explore the full profile